Bionest

Search for an Alzheimer’s Treatment Goes On

Anticipation was high for the results of a Phase 3 trial of Axovant’s experimental drug, interpirdine. Sadly, the potential Alzheimer’s disease treatment failed to meet its co-primary endpoints. Patients with mild to moderate Alzheimer’s disease who were treated for 24 weeks with 35 mg interpirdine, along with the existing Alzheimer’s disease drug Aricept, failed to...

Bionest

Alzheimer’s Disease and the Diagnostic Dilemma

Head over to LinkedIn to read an article by our principal consultant Rachel Laing as part of our continuing commentary on Alzheimer’s Disease. https://www.linkedin.com/pulse/alzheimers-disease-diagnostic-dilemma-rachel-laing/  

Bionest

Diagnosing Alzheimer’s Disease — Part 2

As we wrote in our last post, the ability to accurately diagnose Alzheimer’s disease before a person’s death has been problematic. Experts estimate that a third or more of patients’ cognitive impairment or dementia may be inaccurately diagnosed. As a result, such patients may not benefit from the treatments they do receive or may have...

Bionest

New Developments on the Alzheimer’s Disease Diagnostic Front — Part I

In July, we attended the Alzheimer’s Association International Conference in London. The big news at the meeting was on the diagnostics front.  In the aftermath of the recent string of trial failures, diagnostic tools have become a critical area of focus, in the hopes that patient diagnosis and selection can be improved.   Accurately diagnosing...

Bionest

Alzheimer’s Disease Part Three: Meeting 2025 Goals

  In early 2011, the National Alzheimer’s Project was formed — a strategic plan aimed at addressing the looming health care crisis posed by the disease and the aging population. Its aim: to coordinate research efforts across the U.S. federal government with the goal of preventing or effectively treating Alzheimer’s Disease by 2025. Since then,...

Bionest

Alzheimer’s Disease: Part One – Another One Bites the Dust

Alzheimer’s Disease: Part One – Another one bites the dust, but a possible glimmer of hope on the horizon   On February 14, Merck halted the Phase 3 trial of its Alzheimer’s disease drug candidate, verubecestat, after independent analysis showed that the drug had “virtually no chance of working.” This late stage failure was just the...